Spero Therapeutics, Inc.
SPRO • NASDAQ
Spero Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Esther Rajavelu, with a market cap of $134.9M.
CEOEsther Rajavelu
Next Earnings
Upcoming earnings announcement for Spero Therapeutics, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.18
Earnings History
Past 12 earnings reports for Spero Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | Q4 2025 | $0.53Est: -$0.25 | +312.0% | $41.3M | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.13Est: -$0.25 | +48.0% | $5.4M | — | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.03Est: -$0.34 | +91.2% | $14.2M | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.25Est: -$0.55 | +54.5% | $5.9MEst: $11.0M | -46.6% | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.38Est: -$0.31 | -22.6% | $15.0MEst: $6.2M | +142.6% | 10-K |
| Nov 14, 2024 | Q3 2024 | -$0.32Est: -$0.36 | +11.1% | $13.5MEst: $7.7M | +75.6% | 10-Q |
| Aug 5, 2024 | Q2 2024 | -$0.33Est: -$0.38 | +13.2% | $10.2MEst: $3.3M | +211.8% | 10-Q |
| May 15, 2024 | Q1 2024 | -$0.24Est: -$0.04 | -500.0% | $9.3MEst: $21.5M | -57.0% | 10-Q |
| Mar 13, 2024 | Q4 2023 | $0.96Est: -$0.10 | +1060.0% | $73.5MEst: $18.6M | +294.7% | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.06Est: -$0.03 | -100.0% | $25.5MEst: $15.0M | +70.2% | — |
| Aug 10, 2023 | Q2 2023 | -$0.23Est: -$0.34 | +32.4% | $2.7MEst: $1.1M | +153.8% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.25Est: -$0.33 | +24.2% | $2.1MEst: $1.0M | +106.9% | — |